NASDAQ:ADXS - Advaxis Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $0.35 -0.02 (-5.41 %) (As of 01/17/2019 04:00 PM ET)Previous Close$0.37Today's Range$0.32 - $0.3952-Week Range$0.18 - $3.30Volume544,600 shsAverage Volume1.60 million shsMarket Capitalization$15.91 millionP/E Ratio-0.27Dividend YieldN/ABeta2.92 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Advaxis, Inc., a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of Listeria monocytogenes (Lm) technology based immunotherapies in the United States. It is developing Axalimogene filolisbac and ADXS-Dual that are Lm-LLO immunotherapy product candidates for the treatment of human papilloma virus associated cancers, including cervical, and head and neck cancers. The company is also developing Axalimogene filolisbac for the treatment of anal cancer; ADXS-PSA, an Lm-LLO immunotherapy product candidate, which is designed to target the prostate specific antigen associated with prostate cancer; and ADXS-NEO, an individualized Lm technology antigen delivery product candidate that is designed to create individualized therapies by activating the patient's immune system to respond against multiple mutations or neoantigens. In addition, it is developing ADXS-HOT for generating potent anti-cancer immunity; and ADXS-HER2, an Lm technology antigen delivery product candidate that is designed to target HER2 expressing solid tumors, including human and canine osteosarcoma. The company has collaboration and licensing agreements with Bristol-Myers Squibb Company; Amgen Inc.; Sellas Life Science Group; Merck & Co., Inc.; MedImmune/AstraZeneca PLC; Especificos Stendhal SA de CV; Aratana Therapeutics Inc.; and Global BioPharma Inc. Advaxis, Inc. was founded in 2002 and is based in Princeton, New Jersey. Receive ADXS News and Ratings via Email Sign-up to receive the latest news and ratings for ADXS and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ADXS Previous Symbol CUSIPN/A Webwww.advaxis.com Phone609-452-9813Debt Debt-to-Equity RatioN/A Current Ratio2.21 Quick Ratio3.95Price-To-Earnings Trailing P/E Ratio-0.27 Forward P/E Ratio-0.50 P/E GrowthN/A Sales & Book Value Annual Sales$6.06 million Price / Sales3.05 Cash FlowN/A Price / Cash FlowN/A Book Value$1.32 per share Price / Book0.27Profitability EPS (Most Recent Fiscal Year)($1.29) Net Income$-66,510,000.00 Net Margins-1,096.88% Return on Equity-187.23% Return on Assets-95.05%Miscellaneous Employees108 Outstanding Shares52,830,000Market Cap$15.91 million OptionableOptionable Advaxis (NASDAQ:ADXS) Frequently Asked Questions What is Advaxis' stock symbol? Advaxis trades on the NASDAQ under the ticker symbol "ADXS." How were Advaxis' earnings last quarter? Advaxis, Inc. (NASDAQ:ADXS) announced its quarterly earnings results on Thursday, January, 10th. The biotechnology company reported ($0.29) EPS for the quarter, missing the Zacks' consensus estimate of ($0.15) by $0.14. The biotechnology company had revenue of $1.13 million for the quarter, compared to analysts' expectations of $1.10 million. Advaxis had a negative net margin of 1,096.88% and a negative return on equity of 187.23%. View Advaxis' Earnings History. When is Advaxis' next earnings date? Advaxis is scheduled to release their next quarterly earnings announcement on Monday, March 11th 2019. View Earnings Estimates for Advaxis. What price target have analysts set for ADXS? 3 Wall Street analysts have issued 1-year target prices for Advaxis' stock. Their forecasts range from $2.00 to $5.00. On average, they anticipate Advaxis' share price to reach $3.00 in the next twelve months. This suggests a possible upside of 757.1% from the stock's current price. View Analyst Price Targets for Advaxis. What is the consensus analysts' recommendation for Advaxis? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Advaxis in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Advaxis. Has Advaxis been receiving favorable news coverage? Press coverage about ADXS stock has trended negative on Thursday, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Advaxis earned a media sentiment score of -2.8 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 2.0 out of 10, indicating that recent press coverage is very unlikely to have an impact on the stock's share price in the next several days. Who are some of Advaxis' key competitors? Some companies that are related to Advaxis include IMMUTEP LTD/S (IMMP), Sienna Biopharmaceuticals (SNNA), Otonomy (OTIC), Sesen Bio (SESN), Alimera Sciences (ALIM), Oramed Pharmaceuticals (ORMP), Ophthotech (OPHT), Synergy Pharmaceuticals (SGYP), NewLink Genetics (NLNK), Melinta Therapeutics (MLNT), Innovate Biopharmaceuticals (INNT), Conatus Pharmaceuticals (CNAT), Arcturus Therapeutics (ARCT), Adial Pharmaceuticals (ADIL) and Aquinox Pharmaceuticals (AQXP). Who are Advaxis' key executives? Advaxis' management team includes the folowing people: Dr. Robert G. Petit, Exec. VP & Chief Scientific Officer (Age 58)Mr. Anthony A. Lombardo, Exec. Officer (Age 69)Mr. Kenneth A. Berlin, Pres, CEO and Director (Age 54)Ms. Molly Henderson CPA, MBA, Exec. VP & CFO (Age 47)Noelle Heber, Sr. Director of Corp. Communications & Gov. Affairs Who are Advaxis' major shareholders? Advaxis' stock is owned by a number of of retail and institutional investors. Top institutional investors include Virtu Financial LLC (0.33%). Company insiders that own Advaxis stock include Adage Capital Partners Gp, LL, Anthony A Lombardo, Robert Petit, Roni Appel and Sara Bonstein. View Institutional Ownership Trends for Advaxis. Which institutional investors are buying Advaxis stock? ADXS stock was acquired by a variety of institutional investors in the last quarter, including Virtu Financial LLC. View Insider Buying and Selling for Advaxis. How do I buy shares of Advaxis? Shares of ADXS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Advaxis' stock price today? One share of ADXS stock can currently be purchased for approximately $0.35. How big of a company is Advaxis? Advaxis has a market capitalization of $15.91 million and generates $6.06 million in revenue each year. The biotechnology company earns $-66,510,000.00 in net income (profit) each year or ($1.29) on an earnings per share basis. Advaxis employs 108 workers across the globe. What is Advaxis' official website? The official website for Advaxis is http://www.advaxis.com. How can I contact Advaxis? Advaxis' mailing address is 305 COLLEGE ROAD EAST, PRINCETON NJ, 08540. The biotechnology company can be reached via phone at 609-452-9813 or via email at [email protected] MarketBeat Community Rating for Advaxis (NASDAQ ADXS)Community Ranking: 2.5 out of 5 ( )Outperform Votes: 286 (Vote Outperform)Underperform Votes: 285 (Vote Underperform)Total Votes: 571MarketBeat's community ratings are surveys of what our community members think about Advaxis and other stocks. Vote "Outperform" if you believe ADXS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ADXS will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/17/2019 by MarketBeat.com StaffFeatured Article: What are the benefits of a balanced fund?